To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Cincinnati-based biopharma ...

Leadership team comprises executives from CinCor Pharma, acquired by AstraZeneca in 2023 for up to $1.8 billion NATICK, Mass., Sept. 16, 2025 /PRNewswire/ -- AllRock Bio Inc., a clinical-stage ...

WALTHAM, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that it has entered into a definitive agreement with AstraZeneca under which AstraZeneca has agreed ...

In this episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock welcomes Marc de Garidel, CEO of CinCor Pharma, which was just recently sold to AstraZeneca for more than $1 billion USD.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Before CinCor Pharma Inc. agreed ...

Investors will receive $26 in cash for each CinCor share Astra shares fell as much as 1.4 per cent in London while CinCor more than doubled in New York, trading as high as $27.85. Reuters AstraZeneca ...

New Delhi: AstraZeneca said on Monday it will buy U.S.-based clinical-stage biopharmaceutical firm CinCor Pharma Inc in a deal valued at about $1.8 billion to strengthen its pipeline of heart and ...

CinCor Pharma, Inc. (NASDAQ: CINC) is a clinical-stage biopharmaceutical company, which is focused on the research and development of treatments for cardio-renal diseases. Shares of the biopharma ...

On the face of it, Pascal Soriot’s new deal ought to raise his shareholders’ blood pressure. The boss of $221 billion pharma giant AstraZeneca has agreed to buy CinCor Pharma for up to $1.8 billion.

Gainers: CinCor Pharma (CINC) +137%. Amryt Pharma (AMYT) +107%. Albireo Pharma (ALBO) +93%. Revance Therapeutics (RVNC) +40%. CureVac (CVAC) +28%. Losers: Calithera ...

AstraZeneca Plc agreed to buy US biotech CinCor Pharma Inc. for as much as $1.8 billion to gain a promising new treatment for hypertension and kidney disease. The deal is the first sizable one for ...